My Trial Community is an insights-driven patient platform that is shaping the clinical trial process by: educating Janssen trial participants on the intricacies of clinical trials, empowering them with a selection of their own personal data and study results, and engaging them as valued stakeholders through more regular feedback loops. Janssen is proud to share the development and launch journey of this patient-centered and insights-based solution.

This session will look to explore how early and consistent engagement with potential trial participants will support higher enrollment and retention rates, while also positively impacting screen failures.  It will address how this is accomplished as well as a case study demonstrating early results.

During this session, compelling insights from discussions with patients on barriers to trial participation will be reviewed. We will also explore feedback as to how research access and the trial experience can be improved and discuss practical methods for addressing these challenges.

COVID-19 racial and ethnic disparities have laid bare the need for clinical trial infrastructures that are responsive to the needs of underrepresented patient populations. Short-term, study-level strategies to increase diversity in clinical trials are inadequate to address complex barriers that limit minority patient populations’ participation in COVID-19 clinical trials. Panelists will discuss lessons learned about the unique role that sponsors and sites can play in mobilizing long-term, multi-stakeholder strategies to increase diversity in COVID-19 clinical trials and beyond.

Despite known differences in disease prevalence and therapy response across ethnicities and genders, women and minority groups have been historically underrepresented in clinical trials, limiting findings on response from the full breadth of potential patients. How can we ensure that our commitment to addressing unmet need is reflected in complete, diverse patient datasets? The solution begins long before the first patient is enrolled in a trial. This talk will discuss the urgent need for increased diversity within the clinical trials space at every level, from initial study design through final read-out.

Designing an inclusive clinical trial that is representative of the population being studied might feel daunting, but with planning and thoughtful collaborations, it can be achieved. Hear about various ways to better engage the communities you are looking to serve so that a diverse, representative population has the opportunity to participate in the process of bringing treatments to market to address unmet need.

Join us as we dive into the data from multiple recent direct-to-patient surveys to reveal how opinions from diverse population segments impact study recruitment. In this session we’ll discuss the varied concerns around participation as well as what we can do to address them.

Overview of the Clinical Trial Solutions at Tempus which support precision patient identification and recruitment for oncology clinical trials through the TIME Trial program, a rapid activation Just-in-Time network of research-experienced clinical trial sites

Watch a live demonstration of protocol design utilizing real-world data on the TriNetX platform for a phase III cardiovascular randomized controlled trial, and a subsequent label expansion.

Clinical trial planning is one of the most complex and difficult aspects of the clinical trial process, with multiple factors impacting enrollment. Inaccurate forecasting can lead to misallocation of resources and downstream bottlenecks. How can we use the data we have to do a better job of predicting enrollment?

Study enrollment planning shouldn’t be based on clinical data alone. How can we utilize the wealth of lifestyle and behavioral data available to better understand the factors that will influence an individual’s decision to participate in a clinical trial? Let’s explore the data healthcare marketers commonly analyze to develop audience models in the context of clinical trial enrollment planning.

The video for this session isn’t available here; to access a recording of this session, please email Sarah McKeown-Cannon at sarah.mckeowncannon@publicislangland.com.

This case study will share the strategy behind the building of an enrollment modelling tool, detailing each step throughout the process.  Gain lessons from AbbVie’s experience building and implementing the tool, steps taken to improve its predictive power and accuracy, and results to date.

Founded in 2006, Highthinkmed is the fastest growing clinical CRO in China with over 800 full time employees, providing one-stop clinical services including clinical operation, medical affairs, data management, biostatistics, pharmacovigilance, regulatory affairs etc. Highthinkmed owes its own eCTD system meeting requirements of FDA, EMA and NMPA with a professional team providing eCTD submission services. Highthinkmed welcomes all partners across the world for international collaboration.

Different endpoints derived from wearables can require very different wearable sensors.  Unfortunately, qualifying and integrating different wearables often from different vendors can be time-consuming and uncertain.  Learn how Shimmer Research is addressing this challenge by introducing a series of wearables that are all part of its highly flexible Verisense platform.

Cmed Technology CTO, Dr. Tim Corbett-Clark shares his views on the current landscape within clinical trials, discussing the challenges that point and unified solutions bring. He also examines how to best optimize clinical trial data workflows by bringing the tech to data, removing the silos, and eliminating the barriers to getting holistic data for total control and visibility from phase one to four.